Your browser doesn't support javascript.
loading
Effect of pre-transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis.
Cyriac, Sunu; Prem, Shruti; Salas, Maria Queralt; Chen, Shiyi; Al-Shaibani, Zeyad; Lam, Wilson; Law, Arjun; Gupta, Vikas; Michelis, Fotios V; Kim, Dennis Dong Hwan; Lipton, Jeffrey; Kumar, Rajat; Mattsson, Jonas; Viswabandya, Auro.
Afiliação
  • Cyriac S; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Prem S; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Salas MQ; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Chen S; Department of Biostatistics, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Al-Shaibani Z; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Lam W; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Law A; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Gupta V; Leukemia Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Michelis FV; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Kim DDH; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Lipton J; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Kumar R; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Mattsson J; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
  • Viswabandya A; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Eur J Haematol ; 107(5): 517-528, 2021 Nov.
Article em En | MEDLINE | ID: mdl-34260760
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Antígenos CD34 / Inibidores de Proteínas Quinases / Janus Quinase 1 / Janus Quinase 2 / Mielofibrose Primária Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Antígenos CD34 / Inibidores de Proteínas Quinases / Janus Quinase 1 / Janus Quinase 2 / Mielofibrose Primária Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article